MorphoSys AG is a biopharmaceutical company founded in 1992. The company is headquartered near Munich, Germany and has a wholly owned subsidiary, MorphoSys US Inc., in Boston MA in the US.
Company profile
Ticker
MOR, MPSYF
Exchange
Website
CEO
Simon Moroney
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
MOR stock data
Latest filings (excl ownership)
6-K
Current report (foreign)
18 Mar 24
SC14D9C
Written communication relating to third party tender offer
15 Mar 24
6-K
Current report (foreign)
15 Mar 24
SC14D9C
Written communication relating to third party tender offer
14 Mar 24
6-K
Current report (foreign)
14 Mar 24
6-K
Current report (foreign)
14 Mar 24
SC14D9C
Written communication relating to third party tender offer
13 Mar 24
6-K
Non-Financial Group Report 2023
13 Mar 24
20-F
2023 FY
Annual report (foreign)
13 Mar 24
6-K
Current report (foreign)
12 Mar 24
Latest ownership filings
SC 13G
GOLDMAN SACHS GROUP INC
11 Mar 24
SC 13G/A
Kynam Capital Management, LP
8 Mar 24
SC 13G/A
T. Rowe Price Investment Management, Inc.
16 Feb 24
SC 13G
Kynam Capital Management, LP
14 Feb 24
SC 13G
T. Rowe Price Investment Management, Inc.
14 Feb 24
SC 13G
T. Rowe Price Investment Management, Inc.
14 Feb 23
SC 13G/A
FMR LLC
8 Feb 21
SC 13G/A
BlackRock Inc.
9 Oct 20
SC 13G
Beneficial ownership report
7 Feb 20
SC 13G/A
MorphoSys AG
7 Feb 20
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q3 2023
7.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 40 |
Opened positions | 9 |
Closed positions | 8 |
Increased positions | 17 |
Reduced positions | 11 |
13F shares | Current |
---|---|
Total value | 21.75 bn |
Total shares | 11.52 mm |
Total puts | 36.60 k |
Total calls | 6.10 k |
Total put/call ratio | 6.0 |
Largest owners | Shares | Value |
---|---|---|
T. Rowe Price Investment Management | 7.69 mm | $51.66 mm |
Logos Global Management | 950.00 k | $6.38 bn |
Hudson Bay Capital Management | 455.00 k | $3.06 bn |
Ghost Tree Capital | 400.00 k | $2.69 bn |
Knott David M Jr | 345.00 k | $2.32 mm |
ExodusPoint Capital Management | 255.56 k | $1.72 mm |
AlphaCentric Advisors | 185.00 k | $1.24 bn |
Point72 Asset Management | 174.82 k | $1.17 bn |
Marshall Wace | 162.67 k | $1.09 bn |
Optiver Holding B.V. | 144.04 k | $967.96 mm |
News
MorphoSys Reports Prelim 2023 and Q4 Monjuvi US Net Product Sales of $92.0M and $24.1M, Expects 2024 US Net Product Sales of $80M-$95M
30 Jan 24
Philips Reports Q4 Results, Joins Ryanair And Other Big Stocks Moving Lower In Monday's Pre-Market Session
29 Jan 24
Why TransCode Therapeutics Shares Are Trading Lower By Over 24%? Here Are Other Stocks Moving In Friday's Mid-Day Session
19 Jan 24
Why Super Micro Computer Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket
19 Jan 24
12 Health Care Stocks Moving In Friday's Pre-Market Session
19 Jan 24
Press releases
MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liability
30 Jan 24
Thinking about buying stock in Morphosys, Iovance Biotherapeutics, Bank of America, Energy Fuels, or China Recycling Energy Corporation?
16 Jan 24
MorphoSys to Present at the 42nd Annual J.P. Morgan Healthcare Conference
8 Jan 24